Date published: 2026-7-7

1-800-457-3801

SCBT Portrait Logo
Seach Input

MetRS CRISPR Activation Plasmid (h): sc-402763-ACT

0.0(0)
Write a reviewAsk a question

Datasheets
  • Target species: human
  • 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
  • MetRS CRISPR Activation Plasmid (h) is a synergistic activation mediator (SAM) transcription activation system designed to specifically upregulate gene expression
  • MetRS CRISPR Activation Plasmid (h) consists of three plasmids at a 1:1:1 mass ratio: a plasmid encoding the deactivated Cas9 (dCas9) nuclease (D10A and N863A) fused to the transactivation domain VP64, and a blasticidin resistance gene; a plasmid encoding the MS2-p65-HSF1 fusion protein, and a hygromycin resistance gene; a plasmid encoding a target-specific 20 nt guide RNA fused to two MS2 RNA aptamers, and a puromycin resistance gene
  • The resulting SAM complex binds to a site-specific region approximately 200-250 nt upstream of the transcriptional start site and provides robust recruitment of transcription factors for highly efficient gene activation
  • gRNAs encoded by MetRS CRISPR Activation Plasmid (h) and MetRS CRISPR Activation Plasmid (h2) target distinct regulatory regions upstream of the MARS transcriptional start site. One or both designs may be available
  • Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: MetRS Antibody (H-1): sc-166850
    Gene Editing Promo Banner

    Ordering Information

    Product NameCatalog #UNITPriceQtyFAVORITES

    MetRS CRISPR Activation Plasmid (h)

    sc-402763-ACT
    20 µg
    $397.00

    MetRS CRISPR Activation Plasmid (h2)

    sc-402763-ACT-2
    20 µg
    $397.00

    Human MARS encodes methionyl‑tRNA synthetase (MetRS), a class I aminoacyl‑tRNA synthetase that ligates methionine to initiator and elongator tRNA^Met, establishing translational initiation and sustaining global protein synthesis. MetRS activity connects amino acid availability to ribosome output and proteostasis, influencing stress responses such as the integrated stress response and mTOR-linked nutrient signaling through its impact on translation capacity. As a core component of cytosolic translation machinery, altered MARS expression or function can perturb cellular growth programs, mitochondrial and ER homeostasis via proteome imbalance, and adaptive responses to amino acid limitation. Dysregulation of translation-related factors, including aminoacyl‑tRNA synthetases, is frequently studied in the context of neurodevelopmental phenotypes, cancer cell fitness, and inflammatory signaling where translational control shapes cell state.

    MetRS CRISPR Activation Plasmid (h) provides a targeted, non-destructive approach to upregulating endogenous MARS expression without altering the underlying DNA sequence.

    MetRS CRISPR Activation Plasmid (h) is a three-plasmid synergistic activation mediator (SAM) system engineered for highly efficient, site-specific transcriptional upregulation of the MARS locus in human cell lines. The system is built around a catalytically inactive Cas9 (dCas9) carrying two inactivating mutations (D10A and N863A) that eliminate nuclease activity while preserving DNA binding. This dCas9 is fused to VP64, a potent transcriptional activator, and is co-expressed with a blasticidin resistance gene for selection. The second plasmid encodes the MS2-p65-HSF1 fusion protein, a secondary activator complex that works in concert with dCas9-VP64, alongside a hygromycin resistance gene. The third plasmid encodes a target-specific 20 nt sgRNA fused to two MS2 RNA aptamers that recruit the MS2-p65-HSF1 complex to the activation site, accompanied by a puromycin resistance gene. The three plasmids are delivered at a 1:1:1 mass ratio for balanced expression of all system components.

    Once assembled at the target locus, the SAM complex binds within approximately 200 bp upstream of the MARS transcriptional start site, where VP64, p65, and HSF1 act in concert to recruit transcriptional machinery and drive upregulation of endogenous MetRS expression. Unlike nuclease-active Cas9, dCas9 does not introduce double-strand breaks or modify the genomic sequence, preserving the native MARS locus and enabling the study of MetRS-dependent transcriptional responses at the endogenous locus, making it a valuable tool for functional studies, target gene identification, and the modeling of MetRS pathway restoration in tumor cells with silenced or reduced MARS expression.

    For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.